Cancer drug study placed on hold after patient death
US regulators have placed on hold a clinical trial testing a combination of Advaxis’ axalimogene filolisbac and AstraZeneca’s Imfinzi after a patient died from respiratory failure.
Read More
Tag: axalimogene filolisbac
- Ipsen announces new data on Dysport in neurological disease
- PMGroup Worldwide Ltd welcomes MAD World Summit
- Argenx receives review from FDA for VYVGART in seronegative gMG
- Nuclera extends Series C funding to advance antibody engineering
- Cellistic launches new iPSC-based platforms to expand immuno-oncology therapies
